Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Prevention of Cardiotoxicity in Cancer Patients Receiving Anthracyclines
NCT05271162Phase 3Active, not recruiting
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Sep 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cardiotoxicity comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Cancer Treatment-Related Cardiac Dysfunction at 12 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT05271162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271162.